Welcome to the Steinman Lab
 |
 |
 |
 |
About Us
Our laboratory is dedicated to understanding the pathogenesis of autoimmune diseases, particularly multiple sclerosis and neuromyelitis optica.
We have developed several new therapies for autoimmunity, including some in Phase 2 clinical trials in multiple sclerosis and type 1 diabetes mellitus, as well as one approved drug, natalizumab.
We have developed microarray technology for detecting autoantibodies to myelin proteins and lipids. We employ a diverse range of molecular and cellular approaches to devise new medications for demyelinating diseases, and to help predict which current medications will work at various stages of these diseases.
Publication highlights
- T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Axtell RC, de Jong BA, Boniface K, van der Voort LF, Bhat R, De Sarno P, Naves R, Han M, Zhong F, Castellanos JG, Mair R, Christakos A, Kolkowitz I, Katz L, Killestein J, Polman CH, de Waal Malefyt R, Steinman L, Raman C. Nat Med. 2010; 16 (4): 406-12
- Inhibitory role for GABA in autoimmune inflammation. Bhat R, Axtell R, Mitra A, Miranda M, Lock C, Tsien RW, Steinman L. Proc Natl Acad Sci U S A. 2010; 107 (6): 2580-5
- Inverse vaccination, the opposite of Jenner's concept, for therapy of autoimmunity. Steinman L, J Intern Med. 2010; 267 (5): 441-51
- Innate and adaptive autoimmunity directed to the central nervous system. Bhat R, Steinman L. Neuron. 2009; 64 (1): 123-32
- PPAR-delta senses and orchestrates clearance of apoptotic cells to promote tolerance. Mukundan L, Odegaard JI, Morel CR, Heredia JE, Mwangi JW, Ricardo-Gonzalez RR, Goh YP, Eagle AR, Dunn SE, Awakuni JU, Nguyen KD, Steinman L, Michie SA, Chawla A. Nat Med. 2009; 15 (11): 1266-72
- Blocking angiotensin-converting enzyme induces potent regulatory T cells and modulates TH1- and TH17-mediated autoimmunity. Platten M, Youssef S, Hur EM, Ho PP, Han MH, Lanz TV, Phillips LK, Goldstein MJ, Bhat R, Raine CS, Sobel RA, Steinman L. Proc Natl Acad Sci U S A. 2009; 106 (35): 14948-53
- A molecular trio in relapse and remission in multiple sclerosis. Steinman L, Nat Rev Immunol. 2009; 9 (6): 440-7
- Nuanced roles of cytokines in three major human brain disorders. Steinman L, J Clin Invest. 2008; 118 (11): 3557-63
- Improved efficacy of a tolerizing DNA vaccine for reversal of hyperglycemia through enhancement of gene expression and localization to intracellular sites. Solvason N, Lou YP, Peters W, Evans E, Martinez J, Ramirez U, Ocampo A, Yun R, Ahmad S, Liu E, Yu L, Eisenbarth G, Leviten M, Steinman L, Garren H. J Immunol. 2008; 181 (12): 8298-307
- Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis. Garren H, Robinson WH, Krasulová E, Havrdová E, Nadj C, Selmaj K, Losy J, Nadj I, Radue EW, Kidd BA, Gianettoni J, Tersini K, Utz PJ, Valone F, Steinman L. Ann Neurol. 2008; 63 (5): 611-20
- Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Han MH, Hwang SI, Roy DB, Lundgren DH, Price JV, Ousman SS, Fernald GH, Gerlitz B, Robinson WH, Baranzini SE, Grinnell BW, Raine CS, Sobel RA, Han DK, Steinman L. Nature. 2008; 451 (7182): 1076-81
- A rush to judgment on Th17. Steinman L, J Exp Med. 2008; 205 (7): 1517-22
- Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial. Bar-Or A, Vollmer T, Antel J, Arnold DL, Bodner CA, Campagnolo D, Gianettoni J, Jalili F, Kachuck N, Lapierre Y, Niino M, Oger J, Price M, Rhodes S, Robinson WH, Shi FD, Utz PJ, Valone F, Weiner L, Steinman L, Garren H. Arch Neurol. 2007; 64 (10): 1407-15
- Protective and therapeutic role for alphaB-crystallin in autoimmune demyelination. Ousman SS, Tomooka BH, van Noort JM, Wawrousek EF, O'Connor KC, Hafler DA, Sobel RA, Robinson WH, Steinman L. Nature. 2007; 448 (7152): 474-9
- Peroxisome proliferator-activated receptor (PPAR)alpha expression in T cells mediates gender differences in development of T cell-mediated autoimmunity. Dunn SE, Ousman SS, Sobel RA, Zuniga L, Baranzini SE, Youssef S, Crowell A, Loh J, Oksenberg J, Steinman L. J Exp Med. 2007; 204 (2): 321-30
- A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Steinman L, Nat Med. 2007; 13 (2): 139-45
- Osteopontin-induced relapse and progression of autoimmune brain disease through enhanced survival of activated T cells. Hur EM, Youssef S, Haws ME, Zhang SY, Sobel RA, Steinman L. Nat Immunol. 2007; 8 (1): 74-83
- What went wrong in the natalizumab trials? Langer-Gould A, Steinman L. Lancet. 2006; 367 (9512): 708-10
- Lipid microarrays identify key mediators of autoimmune brain inflammation. Kanter JL, Narayana S, Ho PP, Catz I, Warren KG, Sobel RA, Steinman L, Robinson WH. Nat Med. 2006; 12 (1): 138-43
- Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin. Dunn SE, Youssef S, Goldstein MJ, Prod'homme T, Weber MS, Zamvil SS, Steinman L. J Exp Med. 2006; 203 (2): 401-12
- Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite. Platten M, Ho PP, Youssef S, Fontoura P, Garren H, Hur EM, Gupta R, Lee LY, Kidd BA, Robinson WH, Sobel RA, Selley ML, Steinman L. Science. 2005; 310 (5749): 850-5
- Design of effective immunotherapy for human autoimmunity. Feldmann M, Steinman L. Nature. 2005; 435 (7042): 612-9
- Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab. Steinman L, Nat Rev Drug Discov. 2005; 4 (6): 510-8
Funding
- The National Multiple Sclerosis Society
Home : National MS Society - The National Institute of Neurological Disorders and Stroke of the NationalInstitutes of Health
National Institute of Neurological Disorders and Stroke (NINDS) - The Guthy-Jackson Charitable Foundation (Neuromyelitis Optica)
Guthy-Jackson Charitable Foundation
Internal Staff Login